AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
15 Dec 2015 03:06 PM
RNS
AZ COMPLETES AGREEMENT WITH PERRIGO
14 Dec 2015 07:56 AM
RNS
Discussions with Acerta Pharma BV
02 Dec 2015 07:00 AM
RNS
Late-Stage Pipeline Conference Call
01 Dec 2015 02:00 PM
RNS
Blocklisting Interim Review
01 Dec 2015 01:00 PM
RNS
Total Voting Rights
23 Nov 2015 07:00 AM
RNS
AZ enters agreement w/ Perrigo for Entocort in US
13 Nov 2015 03:06 PM
RNS
AZD9291 Approved by the US FDA
11 Nov 2015 07:30 AM
RNS
ASTRAZENECA PRICES A $6 BILLION BOND ISSUE
06 Nov 2015 07:00 AM
RNS
AZ acquires ZS Pharma to strengthen CVMD portfolio
05 Nov 2015 07:02 AM
RNS
3rd Quarter Results
04 Nov 2015 09:00 AM
RNS
Notice of Results
02 Nov 2015 01:01 PM
RNS
Total Voting Rights
27 Oct 2015 05:50 PM
RNS
Director/PDMR Shareholding
26 Oct 2015 07:00 AM
RNS
FDA AD COM RECOMMENDS THE APPROVAL OF LESINURAD
16 Oct 2015 07:00 AM
RNS
Saxa/dapa FDC Complete Response Letter from FDA
07 Oct 2015 07:00 AM
RNS
ASTRAZENECA COMPLETES DIVESTMENT OF CAPRELSA
01 Oct 2015 04:15 PM
RNS
Total Voting Rights - Replacement
01 Oct 2015 02:30 PM
RNS
Director/PDMR Shareholding
01 Oct 2015 02:00 PM
RNS
Director/PDMR Shareholding
28 Sep 2015 02:30 PM
RNS
Director/PDMR Shareholding
28 Sep 2015 02:30 PM
RNS
Director/PDMR Shareholding
04 Sep 2015 07:00 AM
RNS
US FDA APPROVES EXPANDED INDICATION FOR BRILINTA
01 Sep 2015 11:30 AM
RNS
Total Voting Rights
01 Sep 2015 07:04 AM
RNS
AstraZeneca and Valeant to partner on brodalumab
28 Aug 2015 04:00 PM
RNS
Director/PDMR Shareholding
24 Aug 2015 07:00 AM
RNS
AstraZeneca appoints Dr Sean Bohen
03 Aug 2015 03:00 PM
RNS
Total Voting Rights
30 Jul 2015 07:01 AM
RNS
Half Yearly Report
29 Jul 2015 09:00 AM
RNS
Notice of Results
27 Jul 2015 11:00 AM
RNS
Confirmation of Change in ADS Ratio
27 Jul 2015 07:00 AM
RNS
AstraZeneca agreement with Genzyme on Caprelsa
17 Jul 2015 11:00 AM
RNS
Holding(s) in Company
17 Jul 2015 07:05 AM
RNS
AZ completes agreement with Tillotts for Entocort
14 Jul 2015 07:00 AM
RNS
IRESSA approved by US FDA
09 Jul 2015 07:32 AM
RNS
Agreement with Tillotts on Entocort
01 Jul 2015 11:00 AM
RNS
Total Voting Rights
26 Jun 2015 12:00 PM
RNS
Change in ADS ratio
25 Jun 2015 11:30 AM
RNS
Publication of Prospectus
16 Jun 2015 02:00 PM
RNS
Director/PDMR Shareholding
03 Jun 2015 03:00 PM
RNS
Holding(s) in Company
01 Jun 2015 03:00 PM
RNS
Total Voting Rights
01 Jun 2015 03:00 PM
RNS
AstraZeneca PLC - Blocklisting Interim Review
26 May 2015 07:01 AM
RNS
UPDATE ON BRODALUMAB DEVELOPMENT PROGRAMME
13 May 2015 03:00 PM
RNS
Holding(s) in Company
08 May 2015 02:00 PM
RNS
Director/PDMR Shareholding
08 May 2015 11:00 AM
RNS
Director/PDMR Shareholding - Replacement
08 May 2015 10:00 AM
RNS
Director/PDMR Shareholding
07 May 2015 02:00 PM
RNS
Director Declaration
01 May 2015 04:00 PM
RNS
Director/PDMR Shareholding
01 May 2015 11:00 AM
RNS
Total Voting Rights

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings